Paragangliomas: Etiology, presentation, and management

Cardiology in Review

Volumn 17, Issue 4, 2009, Pages 159-164

  Joynt, Karen E ^a   Moslehi, Javid J ^a   Baughman, Kenneth L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; AMLODIPINE; AMPHETAMINE; ARABINOSIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DECONGESTIVE AGENT; DOXAZOSIN; DOXORUBICIN; EPIRUBICIN; ESMOLOL; IMATINIB; LEVODOPA; METADRENALIN; METIROSINE; NEUROLEPTIC AGENT; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; OCTREOTIDE; PARACETAMOL; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; RESERPINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VINCRISTINE;

ADRENALIN BLOOD LEVEL; ADRENALIN URINE LEVEL; BLOOD ANALYSIS; BRAIN SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE SYNTHESIS; CATECHOLAMINE URINE LEVEL; CHROMAFFIN CELL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAPHORESIS; DRUG DOSE TITRATION; DRUG MEGADOSE; ENDOCRINE TUMOR; FAMILY HISTORY; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PERIOPERATIVE PERIOD; PHEOCHROMOCYTOMA; REVIEW; SIDE EFFECT; SYMPATHETIC GANGLION; TACHYCARDIA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; URINALYSIS;

ADRENAL GLAND NEOPLASMS; HUMANS; PARAGANGLIOMA, EXTRA-ADRENAL; PHEOCHROMOCYTOMA;

EID: 68049101438     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181a6de40     Document Type: Review

References (45)

1. Beard CM, Sheps SG, Kurland LT, et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58:802-804.
2. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986;220: 225-232.
3. Hartley L, Perry-Keene D. Phaeochromocytoma in Queensland-1970-83. Aust N Z J Surg. 1985;55:471-475.
4. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992;147:1-10.
5. Bravo EL. Pheochromocytoma. Cardiol Rev. 2002;10:44-50.
6. Jeevanandam V, Oz MC, Shapiro B, et al. Surgical management of cardiac pheochromocytoma. Resection versus transplantation. Ann Surg. 1995;221: 415-419.
7. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178-183.
8. Goldstein RE, O'Neill JA Jr, Holcomb GW III, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229:755-764; discussion 764-756.
9. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91: 4505-4509.
10. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002;4:62-72.
11. Manger WM. The vagaries of pheochromocytomas. Am J Hypertens. 2005; 18:1266-1270.
12. Klein I. Endocrine disorders and cardiovascular disease. In: Libby P, Bonow RO, Mann DL, et al, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: Saunders Elsevier; 2008:2033-2048.
13. Bravo EL, Gifford RW Jr. Current concepts. Pheochromocytoma: diagnosis, localization, and management. N Engl J Med. 1984;311:1298-1303.
14. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818.
15. Erlic Z, Neumann HP. Clinical question: When should genetic testing be obtained in a patient with pheochromocytoma or paraganglioma? Clin Endocrinol (Oxf). 2009;70:354-357.
16. Pawlu C, Bausch B, Reisch N, et al. Genetic testing for pheochromo-cytoma-associated syndromes. Ann Endocrinol (Paris). 2005;66:178-185.
17. Muller U, Troidl C, Niemann S. SDHC mutations in hereditary paraganglioma/ pheochromocytoma. Fam Cancer. 2005;4:9-12.
18. Pawlu C, Bausch B, Neumann HP. Mutations of the SDHB and SDHD genes. Fam Cancer. 2005;4:49-54.
19. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;8:155-167.
20. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943-951.
21. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427-1434.
22. Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88:553-558.
23. Adler JT, Meyer-Rochow GY, Chen H, et al. Pheochromocytoma: current approaches and future directions. Oncologist. 2008;13:779-793.
24. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-1466.
25. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
26. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/ paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113: 2020-2028.
27. Eigelberger MS, Duh QY. Pheochromocytoma. Curr Treat Options Oncol. 2001;2:321-329.
28. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92:4069-4079.
29. Steinsapir J, Carr AA, Prisant LM, et al. Metyrosine and pheochromocytoma. Arch Intern Med. 1997;157:901-906.
30. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315-329.
31. Brown ML, Zayas GE, Abel MD, et al. Mediastinal paragangliomas: the mayo clinic experience. Ann Thorac Surg. 2008;86:946-951.
32. Gowdamarajan A, Michler RE. Therapy for primary cardiac tumors: is there a role for heart transplantation? Curr Opin Cardiol. 2000;15:121-125.
33. Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92:1217-1225.
34. Pacak K, Fojo T, Goldstein DS, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst. 2001;93:648-649.
35. Sisson JC, Shapiro B, Shulkin BL, et al. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol. 1999;22:364-370.
36. Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648-658.
37. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134:956-962; discussion 962-953.
38. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006;1073:465-490.
39. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, et al. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf). 2002;57:629-634.
40. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267-273.
41. Nakane M, Takahashi S, Sekine I, et al. Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol. 2003;14:1449-1451.
42. Iwabuchi M, Oki Y, Nakamura H. Palliative chemotherapy for malignant pheochromocytoma: symptomatic palliation of two cases. Intern Med. 1999; 38:433-435.
43. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-406.
44. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13:535-540.
45. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005;90:2110-2116.